Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

SZSC:874 Stock Report

Market Cap: HK$47.5b

Guangzhou Baiyunshan Pharmaceutical Holdings Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Hong Li

Chief executive officer

CN¥1.5m

Total compensation

CEO salary percentage30.6%
CEO tenure7.5yrs
CEO ownershipn/a
Management average tenure7.5yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Hong Li's remuneration changed compared to Guangzhou Baiyunshan Pharmaceutical Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥3b

Jun 30 2024n/an/a

CN¥4b

Mar 31 2024n/an/a

CN¥4b

Dec 31 2023CN¥2mCN¥471k

CN¥4b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥2mCN¥460k

CN¥4b

Sep 30 2022n/an/a

CN¥4b

Jun 30 2022n/an/a

CN¥4b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥2mCN¥456k

CN¥4b

Sep 30 2021n/an/a

CN¥4b

Jun 30 2021n/an/a

CN¥4b

Mar 31 2021n/an/a

CN¥3b

Dec 31 2020CN¥1mCN¥442k

CN¥3b

Sep 30 2020n/an/a

CN¥3b

Jun 30 2020n/an/a

CN¥2b

Mar 31 2020n/an/a

CN¥3b

Dec 31 2019CN¥1mCN¥428k

CN¥3b

Sep 30 2019n/an/a

CN¥3b

Jun 30 2019n/an/a

CN¥3b

Mar 31 2019n/an/a

CN¥4b

Dec 31 2018CN¥1mCN¥382k

CN¥3b

Compensation vs Market: Hong's total compensation ($USD210.86K) is below average for companies of similar size in the Hong Kong market ($USD729.21K).

Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.

CEO

Hong Li (57 yo)

7.5yrs

Tenure

CN¥1,539,030

Compensation

Mr. Hong Li has been General Manager at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited since June 23, 2017 and serves as its Executive Director since June 22, 2018. Mr. Li started his career...

Leadership Team

NamePositionTenureCompensationOwnership
Hong Li
GM & Executive Director7.5yrsCN¥1.54mno data
Ning Cheng
Executive Vice Chairman12.3yrsno datano data
Jun Yang
Executive Vice Chairman4.9yrsno datano data
Changhai Wu
Deputy GM & Executive Director9.9yrsCN¥1.57mno data
Juyan Liu
Executive Directorno datano datano data
Haoshan Zheng
Deputy GM & Director of Business Administration Department5.4yrsCN¥1.41mno data
Xuezhen Huang
Secretary7.7yrsCN¥1.24mno data

7.5yrs

Average Tenure

57yo

Average Age

Experienced Management: 874's management team is seasoned and experienced (7.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hong Li
GM & Executive Director6.5yrsCN¥1.54mno data
Ning Cheng
Executive Vice Chairman12.3yrsno datano data
Jun Yang
Executive Vice Chairman4.9yrsno datano data
Changhai Wu
Deputy GM & Executive Director14.5yrsCN¥1.57mno data
Juyan Liu
Executive Director10.9yrsno datano data
Lung Tak Wong
Independent Non-Executive Director1.6yrsCN¥50.00kno data
Ruiyu Cai
Chairman of the Supervisory Board5.3yrsno datano data
Jinyuan Cheng
Supervisor4.9yrsno datano data
Yajin Chen
Independent Non-Executive Director4.5yrsCN¥120.00kno data
Min Huang
Independent Non-Executive Director4.5yrsCN¥120.00kno data
Huidong Jian
Supervisor3.5yrsno datano data
Sun Baoqing
Independent Non-Executive Director1.6yrsCN¥70.00kno data

4.9yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 874's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 12:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is covered by 29 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhi Xue DiaoAvic Securities Co., Ltd
null nullBOCI Research Ltd.
Feng Qiang SunBOCOM International Securities Limited